Basic information Safety Supplier Related

PNU 100480

Basic information Safety Supplier Related

PNU 100480 Basic information

Product Name:
PNU 100480
Synonyms:
  • PNU 100480
  • (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide
  • Sutezolid
  • (S)-N-((3-(3-fluoro-4-thiomorpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
  • (S)-N-((3-(3-fluoro-4-thiomorpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide(WXC06631)
  • PF-02341272
  • Sutezolid (PNU-100480, PF-02341272)
  • PNU-100480; U-100480; PF-02341272
CAS:
168828-58-8
MF:
C16H20FN3O3S
MW:
353.41
Mol File:
168828-58-8.mol
More
Less

PNU 100480 Chemical Properties

Melting point:
186-187°C
Boiling point:
609.0±55.0 °C(Predicted)
Density 
1.321±0.06 g/cm3(Predicted)
storage temp. 
room temp
solubility 
DMSO: soluble20mg/mL, clear
pka
15.53±0.46(Predicted)
form 
powder
color 
white to beige
optical activity
[α]/D -8 to -12°, c = 1 in chloroform-d
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
22
Safety Statements 
45
More
Less

PNU 100480 Usage And Synthesis

Description

PNU 100480 is an oxazolidinone antibiotic that is active against multidrug resistant tuberculosis. It inhibits the growth of M. tuberculosis replicating and nonreplicating strains (MIC = ~400 ng/ml for both) and of clinical isolates that are susceptible or resistant to a combination of isoniazid , rifampin (rifampicin; ), ethambutol , and streptomycin (; MICs = ≤0.0625-0.5 mg/L). It also inhibits the growth of P. insidiosum and P. aphanidermatum clinical isolates (MICs = 4-64 μg/ml). PNU 100480 (100 mg/kg per day) decreases the number of colony forming units (CFU) in the lung in a mouse model of systemic nonreplicating M. tuberculosis infection.

Uses

Sutezolid is an oxazolidinone antibacterial agent analog. Sutezolid is a promising antimycobacterial agent (tuberculostatic).

Biochem/physiol Actions

Sutezolid (PNU 100480) is an oxazolidinone antimicrobial. Sutezolid inhibits protein synthesis by inhibiting bacterial mRNA translation. Sutezolid is being investigated for the treatment of multiple drug–resistant and extensively drug-resistant tuberculosis. The compound is a less toxic and more potent derivative of linezolid.

in vivo

Sutezolid (PNU-100480) is a thiomorpholinyl analog of linezolid with superior efficacy against M. tuberculosis in the hollow-fiber, mouse, and whole-blood models[3].

IC 50

Oxazolidinone

References

[1] J W C ALFFENAAR. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.[J]. Antimicrobial Agents and Chemotherapy, 2011, 55 3: 1287-1289. DOI: 10.1128/aac.01297-10
[2] MING ZHANG. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.[J]. Antimicrobial Agents and Chemotherapy, 2014: 3217-3223. DOI: 10.1128/aac.02410-14
[3] ERICO S LORETO. In Vitro Activities of Miltefosine and Antibacterial Agents from the Macrolide, Oxazolidinone, and Pleuromutilin Classes against Pythium insidiosum and Pythium aphanidermatum.[J]. Antimicrobial Agents and Chemotherapy, 2018, 62 3. DOI: 10.1128/aac.01678-17

PNU 100480Supplier

UHN Shanghai Research & Development Co., Ltd.
Tel
021-58958002 18930822973
Email
sales@uhnshanghai.com
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Nanjing XiZe Biotechnology CO., Ltd.
Tel
025-58362220 0086-15250997978
Email
sale@njxizebio.com
ShangHai Angti Biotechnology Co., Ltd.
Tel
13764913901
Email
info@angtibio.com